Skip to main content

Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells

Buy Article:

$42.00 + tax (Refund Policy)

Protein kinase CK2 seems to play an essential role in cellular growth regulation as well as in apoptosis. By using a pair of prostate carcinoma cell lines which are either hormone-sensitive (LNCaP cells) or hormone-refractory (PC-3 cells) we analysed the contribution of protein kinase CK2 to their different growth behaviour as well as to apoptosis. We found the same amount of CK2 subunits in both cell lines although the enzymatic activity of CK2 was much higher in the hormone-refractory cells. These results for the first time show a correlation between the specific activity of protein kinase CK2 and specific growth properties of prostate cancer cells. The antiproliferative flavonoid apigenin led to an inhibition of the CK2 activity in both types of cells but only the hormone-sensitive LNCaP cells responded with apoptosis. Thus, these results demonstrate that a high CK2 activity is dispensable for growth and not necessary for a protection against apoptosis in hormone-refractory prostate cancer cells.

Document Type: Research Article

Affiliations: Medizinische Biochemie und Molekularbiologie, Universität des Saarlandes, D-66424 Homburg, Germany

Publication date: 01 June 2003

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content